Definium Therapeutics (DFTX) Competitors

$20.99 -0.36 (-1.69%)

As of 04:00 PM Eastern

DFTX vs. HIMS, CELC, CAI, PACS, and RDNT

Should you buy Definium Therapeutics stock or one of its competitors? MarketBeat compares Definium Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Definium Therapeutics include Hims & Hers Health (HIMS), Celcuity (CELC), Caris Life Sciences (CAI), PACS Group (PACS), and RadNet (RDNT). These companies are all part of the "healthcare" industry.

How does Definium Therapeutics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Hims & Hers Health currently has a consensus price target of $29.50, suggesting a potential upside of 17.70%. Definium Therapeutics has a consensus price target of $37.92, suggesting a potential upside of 80.67%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 2.3% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Hims & Hers Health has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

Definium Therapeutics has a net margin of 0.00% compared to Hims & Hers Health's net margin of -0.56%. Hims & Hers Health's return on equity of 6.10% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Definium Therapeutics	N/A	-100.30%	-69.22%

In the previous week, Hims & Hers Health had 59 more articles in the media than Definium Therapeutics. MarketBeat recorded 75 mentions for Hims & Hers Health and 16 mentions for Definium Therapeutics. Hims & Hers Health's average media sentiment score of -0.01 beat Definium Therapeutics' score of -0.25 indicating that Hims & Hers Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	16 Very Positive mention(s)	10 Positive mention(s)	11 Neutral mention(s)	24 Negative mention(s)	6 Very Negative mention(s)	Neutral
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hims & Hers Health has higher revenue and earnings than Definium Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.37B	2.41	$128.37M	-$0.09	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

Summary

Hims & Hers Health beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Celcuity presently has a consensus price target of $140.20, suggesting a potential upside of 1.83%. Definium Therapeutics has a consensus price target of $37.92, suggesting a potential upside of 80.67%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Celcuity is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.79	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

In the previous week, Definium Therapeutics had 4 more articles in the media than Celcuity. MarketBeat recorded 16 mentions for Definium Therapeutics and 12 mentions for Celcuity. Celcuity's average media sentiment score of 0.65 beat Definium Therapeutics' score of -0.25 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Definium Therapeutics' return on equity of -100.30% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-203.17%	-52.68%
Definium Therapeutics	N/A	-100.30%	-69.22%

Celcuity has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 2.3% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Definium Therapeutics beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Definium Therapeutics compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Caris Life Sciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	5.07	-$68.09M	-$7.61	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

Caris Life Sciences presently has a consensus price target of $27.56, suggesting a potential upside of 89.39%. Definium Therapeutics has a consensus price target of $37.92, suggesting a potential upside of 80.67%. Given Caris Life Sciences' higher possible upside, research analysts clearly believe Caris Life Sciences is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Definium Therapeutics had 3 more articles in the media than Caris Life Sciences. MarketBeat recorded 16 mentions for Definium Therapeutics and 13 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.09 beat Definium Therapeutics' score of -0.25 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Caris Life Sciences has a net margin of 3.75% compared to Definium Therapeutics' net margin of 0.00%. Caris Life Sciences' return on equity of 98.28% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Definium Therapeutics	N/A	-100.30%	-69.22%

27.9% of Definium Therapeutics shares are owned by institutional investors. 7.8% of Caris Life Sciences shares are owned by insiders. Comparatively, 2.3% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Caris Life Sciences beats Definium Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to PACS Group?

PACS Group (NYSE:PACS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

In the previous week, Definium Therapeutics had 4 more articles in the media than PACS Group. MarketBeat recorded 16 mentions for Definium Therapeutics and 12 mentions for PACS Group. PACS Group's average media sentiment score of 0.98 beat Definium Therapeutics' score of -0.25 indicating that PACS Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.9% of Definium Therapeutics shares are owned by institutional investors. 70.1% of PACS Group shares are owned by insiders. Comparatively, 2.3% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PACS Group has a net margin of 4.49% compared to Definium Therapeutics' net margin of 0.00%. PACS Group's return on equity of 26.47% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Definium Therapeutics	N/A	-100.30%	-69.22%

PACS Group has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market.

PACS Group presently has a consensus price target of $45.60, suggesting a potential upside of 21.48%. Definium Therapeutics has a consensus price target of $37.92, suggesting a potential upside of 80.67%. Given Definium Therapeutics' higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

PACS Group has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.12	$191.54M	$1.56	24.06
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

Summary

PACS Group beats Definium Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to RadNet?

Definium Therapeutics (NASDAQ:DFTX) and RadNet (NASDAQ:RDNT) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Definium Therapeutics has a net margin of 0.00% compared to RadNet's net margin of -0.66%. RadNet's return on equity of 2.77% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
RadNet	-0.66%	2.77%	0.97%

RadNet has higher revenue and earnings than Definium Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
RadNet	$2.04B	2.02	-$18.65M	-$0.18	N/A

Definium Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market. Comparatively, RadNet has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Definium Therapeutics currently has a consensus price target of $37.92, suggesting a potential upside of 80.67%. RadNet has a consensus price target of $88.14, suggesting a potential upside of 68.24%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Definium Therapeutics is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 2.3% of Definium Therapeutics shares are held by insiders. Comparatively, 5.6% of RadNet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Definium Therapeutics had 3 more articles in the media than RadNet. MarketBeat recorded 16 mentions for Definium Therapeutics and 13 mentions for RadNet. RadNet's average media sentiment score of 0.29 beat Definium Therapeutics' score of -0.25 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
RadNet	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RadNet beats Definium Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DFTX vs. The Competition

Export

Metric	Definium Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.09B	$466.77M	$6.23B	$12.27B
Dividend Yield	N/A	3.86%	2.80%	5.35%
P/E Ratio	-8.43	3.88	20.14	25.23
Price / Sales	N/A	7,763.50	542.44	73.19
Price / Cash	N/A	13.13	43.26	56.33
Price / Book	7.50	84.20	9.81	6.90
Net Income	-$183.79M	-$96.07M	$3.56B	$333.88M
7 Day Performance	-4.81%	1.30%	0.33%	0.04%
1 Month Performance	-5.24%	0.59%	-0.98%	1.74%
1 Year Performance	220.46%	68.39%	36.19%	32.64%

Definium Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DFTX Definium Therapeutics	2.9723 of 5 stars	$20.99 -1.7%	$37.92 +80.7%	+226.5%	$2.09B	N/A	N/A	40	Earnings Report Analyst Revision
HIMS Hims & Hers Health	3.8159 of 5 stars	$27.25 -0.6%	$32.53 +19.4%	-60.8%	$6.25B	$2.35B	53.43	2,442	Trending News Earnings Report Analyst Forecast Options Volume
CELC Celcuity	1.7527 of 5 stars	$144.98 +15.4%	$134.50 -7.2%	+1,140.5%	$6.07B	N/A	N/A	40	News Coverage Earnings Report Analyst Forecast Gap Down High Trading Volume
CAI Caris Life Sciences	4.3105 of 5 stars	$18.69 +1.2%	$28.86 +54.4%	N/A	$5.22B	$812.03M	N/A	1,846	Insider Trade
PACS PACS Group	3.9261 of 5 stars	$32.55 -1.4%	$44.40 +36.4%	+264.8%	$5.19B	$5.29B	26.47	47,455	Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DFTX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Definium Therapeutics (DFTX) Competitors

DFTX vs. HIMS, CELC, CAI, PACS, and RDNT

How does Definium Therapeutics compare to Hims & Hers Health?

Summary

How does Definium Therapeutics compare to Celcuity?

Summary

How does Definium Therapeutics compare to Caris Life Sciences?

Summary

How does Definium Therapeutics compare to PACS Group?

Summary

How does Definium Therapeutics compare to RadNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Definium Therapeutics (DFTX) Competitors

DFTX vs. HIMS, CELC, CAI, PACS, and RDNT

How does Definium Therapeutics compare to Hims & Hers Health?

Do analysts recommend HIMS or DFTX?

Do institutionals & insiders have more ownership in HIMS or DFTX?

Which has more volatility & risk, HIMS or DFTX?

Is HIMS or DFTX more profitable?

Does the media favor HIMS or DFTX?

Which has preferable earnings and valuation, HIMS or DFTX?

Summary

How does Definium Therapeutics compare to Celcuity?

Do analysts rate CELC or DFTX?

Which has better valuation & earnings, CELC or DFTX?

Does the media prefer CELC or DFTX?

Is CELC or DFTX more profitable?

Which has more volatility & risk, CELC or DFTX?

Do institutionals and insiders hold more shares of CELC or DFTX?

Summary

How does Definium Therapeutics compare to Caris Life Sciences?

Which has better valuation & earnings, CAI or DFTX?

Do analysts rate CAI or DFTX?

Does the media refer more to CAI or DFTX?

Is CAI or DFTX more profitable?

Do institutionals and insiders hold more shares of CAI or DFTX?

Summary

How does Definium Therapeutics compare to PACS Group?

Does the media prefer PACS or DFTX?

Do insiders & institutionals hold more shares of PACS or DFTX?

Is PACS or DFTX more profitable?

Which has more volatility and risk, PACS or DFTX?

Do analysts rate PACS or DFTX?

Which has preferable earnings & valuation, PACS or DFTX?

Summary

How does Definium Therapeutics compare to RadNet?

Is DFTX or RDNT more profitable?

Which has preferable valuation & earnings, DFTX or RDNT?

Which has more volatility & risk, DFTX or RDNT?

Do analysts rate DFTX or RDNT?

Do insiders and institutionals believe in DFTX or RDNT?

Does the media refer more to DFTX or RDNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools